Skip to main content

Table 1 Characteristics of TCGA patients diagnosed with high-grade serous ovarian carcinoma

From: Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity

  Chemo-sensitive Chemo-resistant p-value
No. of patients 97 38  
FIGO Stage    P = 0.2011
 II 9 (9.3) 1 (2.6)  
 III 77 (79.4) 35 (92.1)  
 IV 11 (11.3) 2 (5.3)  
WHO Grade    P = 0.6123
 2 15 (15.5) 4 (10.5)  
 3 81 (83.5) 33(86.8)  
 Unknown 1 (1.0) 1(2.6)  
Residual disease    P = 0.0708
 No Macroscopic disease 27 (27.8) 5 (13.2)  
 1–10 mm 39 (40.2) 23 (60.5)  
 11–20 mm 7 (7.2) 2 (5.3)  
  > 20 mm 16 (16.5) 6 (15.8)  
 NA 8 (8.2) 2 (5.3)  
 Progression Free Survival(median, mons) 19.91 (3.3–87) 9.185 (2.3–15.2) P < 0.0001
 Overall Survival (median, mons) 41.03 (8.8–125.6) 32.835 (6.7–66) P = 0.0047